Any monocarboxylic acid that is phenylacetic acid or its substituted derivatives.
ChEBI ID: 25978
Member | Definition | Role |
---|---|---|
(3,4-dimethoxyphenyl)acetic acid | A phenylacetic acid substituted at positions 3 and 4 by methoxy groups. | homoveratric acid |
2-nitrophenylacetic acid | A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the ortho- position by a nitro group. | (2-nitrophenyl)acetic acid |
4-nitrophenylacetic acid | A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl grup is substituted at the para- position by a nitro group. | (4-nitrophenyl)acetic acid |
isohomovanillic acid | A member of the class of phenylacetic acids that is the 4-O-methyl ether of (3,4-dihydroxyphenyl)acetic acid. | isohomovanillic acid |
nitrohydroxyiodophenylacetate | A member of the class of phenylacetic acids that is phenylacetic acid in which the phenyl group is substituted by iodo, hydroxy and nitro groups at positions 3, 4 and 5 respectively. | (4-hydroxy-3-iodo-5-nitrophenyl)acetic acid |
phenylacetic acid | A monocarboxylic acid that is toluene in which one of the hydrogens of the methyl group has been replaced by a carboxy group. | phenylacetic acid |
robenacoxib | An aromatic amino acid that is 2-amino-5-ethylphenylacetic acid in which one of the amino hydrogens is replaced by a 2,3,5,6-tetrafluorophenyl group. A selective cyclooxygenase 2 inhibitor that is used in veterinary medicine for the relief of pain and inflammation in cats and dogs. | robenacoxib |
Timeframe | Studies, Drugs in This Class (%) | All Drugs % |
---|---|---|
pre-1990 | 215 (22.75) | 18.7374 |
1990's | 185 (19.58) | 18.2507 |
2000's | 265 (28.04) | 29.6817 |
2010's | 223 (23.60) | 24.3611 |
2020's | 57 (6.03) | 2.80 |
Publication Type | Studies, Drugs in This Class (%) | All Drugs (%) |
---|---|---|
Trials | 45 (4.48%) | 5.53% |
Reviews | 32 (3.18%) | 6.00% |
Case Studies | 24 (2.39%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 904 (89.95%) | 84.16% |